文献速递哮喘慢阻肺

哮喘与慢阻肺的新型抗嗜酸性粒细胞药物:靶向可治疗特征

New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
PubMed 文献 · Chest · 2017-06-02

哮喘和慢阻肺是复杂异质的慢性气道炎症疾病,嗜酸性气道炎症被视为最重要的可治疗特征。近十年开发了靶向IL-5、IL-13、IL-4Rα、IgE、TSLP的单克隆抗体及小分子药物,但并非所有患者响应一致,可能与不同分子通路或内型有关,目前缺乏可靠生物标志物预测疗效。

要点

  • 嗜酸性气道炎症是哮喘和慢阻肺最重要的可治疗特征。
  • 抗IL-5、IL-4Rα、IgE、TSLP等生物制剂及小分子药物已获开发。
  • 疗效异质性与不同内型通路有关,亟需可预测响应的生物标志物。

核心结论

  • 嗜酸性气道炎症是哮喘和慢阻肺最具影响力的可治疗特征,靶向该特征的生物制剂和小分子药物已显示前景,但疗效异质性提示需按内型精准选择。
  • 当前缺乏可靠生物标志物区分不同嗜酸性炎症通路,亟需可测量、可重复且能预测和监测生物制剂响应的标志物。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • 靶向IL-5或IL-5受体α的单抗包括美泊利珠单抗、瑞利珠单抗和贝那利珠单抗。
  • 靶向IL-13的单抗包括来金珠单抗和曲罗芦单抗。
  • 靶向IL-4受体α的单抗为度普利尤单抗,靶向IgE的单抗为奥马珠单抗,抗TSLP单抗为特泽鲁单抗。
  • 小分子药物包括前列腺素D2阻滞剂非维匹普兰和替马匹普兰。
  • 尽管临床、功能和炎症特征相似,并非所有患者对新型生物制剂响应一致。

关键数值与推荐

  • 嗜酸性气道炎症由适应性免疫通路(Th2细胞介导)和固有免疫通路(固有淋巴样细胞介导)共同参与。
  • 上述通路在哮喘和慢阻肺中的相对贡献尚未阐明,目前无可靠生物标志物代表不同通路。

临床怎么用

  • 临床可依据嗜酸性气道炎症这一可治疗特征考虑靶向生物制剂或小分子药物。
  • 需注意疗效异质性,不能仅凭临床、功能及炎症特征预测个体响应。

局限性

  • 不同分子通路或内型导致嗜酸性气道炎症的机制尚未明确。
  • 缺乏可靠生物标志物预测和监测新型生物制剂的治疗响应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Asthma and COPD are prevalent chronic inflammatory airway diseases that are responsible for a large global disease burden. Both diseases are complex and heterogeneous, and they are increasingly recognized as overlapping syndromes that may share similar pathophysiologic mechanisms and treatable traits. Eosinophilic airway inflammation is considered the most influential treatable trait of chronic airway disease, and over the last decade, several monoclonal antibodies and small molecule therapies have been developed to target this trait. These include monoclonal antibodies against IL-5 or IL-5 receptor alpha (mepolizumab, reslizumab, and benralizumab), IL-13 (lebrikizumab and tralokinumab), IL-4 receptor alpha (dupilumab), IgE (omalizumab), and anti-thymic stromal lymphopoietin (tezepelumab) and small molecule therapies such as prostaglandin D2 blockers (fevipiprant and timapiprant). Although these novel biologic agents have shown promising results in many patients with asthma and COPD who have eosinophilic airway inflammation, it is evident that not all patients respond equally well, despite similar clinical, functional, and inflammatory characteristics. This heterogeneity in treatment response is probably related to different molecular pathways or endotypes leading to eosinophilic airway inflammation, including adaptive immune pathways mediated by T helper 2 cells and innate immune pathways mediated by innate lymphoid cells. The relative contribution of these pathways in asthma and COPD is not yet clarified, and there are currently no reliable biomarkers that represent the various pathways. Therefore, there is an urgent need for easily measurable and reproducible biomarkers that are linked to underlying pathophysiologic disease mechanisms and can predict and monitor responses to novel biologic agents.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Bel EH, Ten Brinke A. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait! Chest. 2017. PMID: 28583618. doi:10.1016/j.chest.2017.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。